Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab Placebo, Tiragolumab clinical trials

A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, an Anti- TIGIT Antibody, in Combination with Atezolizumab in Chemotherapy-Naive Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study looks at a new drug, tiragolumab, combined with an existing cancer drug, atezolizumab (Tecentriq), for people with a type of lung cancer called non-small cell lung cancer that hasn't been treated with chemotherapy yet. It aims to see how well this combination works.